RGTLF (Argent Biopharma) Other Operating Expense: $-0.06 Mil (TTM As of Dec. 2025)


What is Argent Biopharma Other Operating Expense?

Argent Biopharma RGTLF Other Operating Expense is $-0.06 Mil as of Dec. 2025. The stock has 8 warning signs investors should review.

Argent Biopharma's Other Operating Expense for the six months ended in Dec. 2025 was $0.89 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.06 Mil.

Argent Biopharma's quarterly Other Operating Expense declined from Dec. 2024 ($3.61 Mil) to Jun. 2025 ($-0.95 Mil) but then increased from Jun. 2025 ($-0.95 Mil) to Dec. 2025 ($0.89 Mil).

Argent Biopharma's annual Other Operating Expense increased from Jun. 2023 ($1.34 Mil) to Jun. 2024 ($3.36 Mil) but then declined from Jun. 2024 ($3.36 Mil) to Jun. 2025 ($2.76 Mil).

Argent Biopharma Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Argent Biopharma's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Argent Biopharma Other Operating Expense Chart

Argent Biopharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.40 4.05 1.34 3.36 2.76

Argent Biopharma Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.69 3.23 3.61 -0.95 0.89

Argent Biopharma Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $-0.06 Mil mean?
Argent Biopharma (RGTLF) has a Other Operating Expense of $-0.06 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on Argent Biopharma and its competitors.
Is Argent Biopharma's Other Operating Expense too high?
Argent Biopharma's current Other Operating Expense is $-0.06 Mil.
How does Argent Biopharma's Other Operating Expense compare to ZTS and UTHR?
Argent Biopharma's Other Operating Expense of $-0.06 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Drug Manufacturers company?
A good Other Operating Expense depends on the Drug Manufacturers industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Argent Biopharma and its competitors. Argent Biopharma's current Other Operating Expense is $-0.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argent Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Argent Biopharma (RGTLF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 25% above its estimated fair value. The current Other Operating Expense is $-0.06 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Argent Biopharma (RGTLF), the current Other Operating Expense is $-0.06 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Argent Biopharma Business Description

Other Exchanges H5O0:GermanyRGT:Australia
Address 295 Rokeby Road, Suite 1, Subiaco, WA, AUS, 6008
Argent Biopharma Ltd is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. Its assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others. Its geographic areas are Malta, Slovenia and others, and Australia. The group generates the majority of its revenue from Slovenia and others.